Chronic renal failure: A cardiovascular risk factor

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Fort, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Cardiovascular risk; Chronic renal disease; Morbi mortality

Indexed keywords

CALCIUM; HOMOCYSTEINE; PHOSPHORUS;

ADRENERGIC SYSTEM; ANEMIA; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; CALCIUM METABOLISM; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PHOSPHATE METABOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; UREMIA;

EID: 33748291394     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09906.x     Document Type: Conference Paper

References (51)

1. K/DOQI: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39:S1-S246, 2002
2. LINDNER A, CHARRA B, SHERRARD DJ, SCRIBNER BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
3. PARFREY PS, FOLEY RN: The clinical epidemiology of cardiac disease in chronic uremia. J Am Soc Nephrol 10:1053-1058, 1999
4. RAINE AEG, SCHWARZ U, RITZ E: The patient with uremia: Hypertension and cardiac problems, in Oxford Textbook of Clinical Nephrology, edited by Davison AM, Oxford, Oxford University Press, 1998, pp 1885-1919
5. RENAL DATA SYSTEM: USRDS 2003 Annual report: Atlas of end-stage renal disease in the United States, Bethesda, MD, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, 2003
6. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23, 1998
7. PARFREY PS, COLLINGWOOD P, FOLEY RN, BAHRLE A: Images in Nephrology. Left ventricular disorders detected by mode echocardiography in chronic uraemia. Neprol Dial Transplant 11:1328-1331, 1996
8. RUILOPE LM, VAN VELDHUISEN DJ, RITZ E, LUSCHER TF: Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38:1782-1787, 2001
9. RITZ E: Minor renal dysfunction: An emerging independent cardiovascular risk factor. Heart 89:963-964, 2003
10. GO AS, CHERTOW GM, FAN D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305, 2004
11. HENRY RA, KOSTENSE PJ, BOS G, et al: Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 62:1402-1407, 2002
12. ABRAMSON JL, JURKOVITZ CT, VACCARINO V, et al: Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 64:610-615, 2003
13. FLACK J, NEATON J, DANIELS B, ESUNGE P: Ethnicity and renal disease: lessons from the Multiple Risk Factor Intervention Trial and Treatment of Mild Hypertension Study. Am J Kidney Dis 21(Suppl 4):31-40, 1993
14. HANSSON L, ZANCHETTI A, CARRUTHERS SG, et al: for the HOT study group: Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755-1762, 1998
15. COCKCROFT DW, GAULT MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
16. CHONABIAN AV, BAKRIS GL, BLACK HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 7. Hypertension 42:1206-1252, 2003
17. MCMAHON DC, ROGER SD, LEVIN A: FOR THE SLIMHEART INVESTIGATORS GROUP. Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease. J Am Soc Nephrol 15:1640-1647, 2004
18. LONDON GM: Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 16:85-94, 2003
19. ESCHBACH JW, ADAMSON JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1, 1985
20. CANNATA JB, DÍAZ LÓPEZ JB: Alteraciones hematológicas en la insuficiencia renal crónica, in Insuficiencia Renal Crónica, Diálisis y Trasplante Renal, 2nd ed., edited by Llach F, Valderrábano F, Madrid, Norma, 1997, pp 423-447
21. PARFREY PS, FOLEY RN, HARNETT JD, et al: Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 11:1277-1285, 1996
22. LEVIN A, THOMPSON CR, ETHIER J, et al: Left ventricular mass index increase in early renal disease: Impact of decline on hemoglobin. Am J Kidney Dis 34:125-134, 1999
23. AL-AHMAD A, RAND WM, MANJUNATH G, et al: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962, 2001
24. COLLINS AJ, LI S, GILBERSTON DT, et al: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int (Suppl 87):S24-31, 2003
25. HOLLAND DC, LAM M: Predictors of hospitalization and death among predialysis patients: A retrospective cohort study. Neprol Dial Transplant 15:650-658, 2000
26. PORTOLÉS J, TORRALBO A, MARTIN P, et al: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
27. MOCKS J, FRANKE W, EHMER B, et al: Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients, in Pathogenetic and Therapeutic Aspects of Chronic Renal Failure, edited by Koch KM, Stein G, New York, Marcel Dekker, 1997, pp 163
28. MORBIDITY ANDMORTALITY OF RENAL DIALYSIS: An NIH consensus conference statement. Consensus Development Conference Panel. Ann Intern Med 121:62, 1994
29. DELANO BG: Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14:14, 1989
30. SILVERBERG DS, WEXLER D, BLUM M, et al: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35:1737-1744, 2000
31. LOCATELLI F, ALJAMA P, BARANY P, et al: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Neprol Dial Transplant 19(Suppl 2):1-44, 2004
32. BLOCK GA, HULBERT-SHEARON TE, et al: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
33. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
34. SAFAR ME, BLACHER J, PANNIER B, et al: Central pulse pressure and mortality in end-stage renal disease. Hypertension 39:735-738, 2002
35. GOODMAN WG, LONDON G, ON BEHALF OF THE VASCULAR CALCIFICATION WORK GROUP: Vascular calcification in chronic kidney disease. Am J Kidney Dis 43:572-579, 2004
36. KETTELER M, VERMEER C, WANNER C, et al: Novel insights into uremic vascular calcification: Role of matrix Gla protein and alpha-2-Heremans Schmid glycoproteins/fetuin. Blood Purif 20:473-476, 2002
37. EHRLICH JE, RUMBERGER JA: Detection and clinical management of cardiovascular calcification in ESRD. Nephrol Dial Transplant 33:306-313, 2004
38. CONVERSE RL, JACOBSEN TN, TOTO RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
39. KOOMANS HA, BLANKESTIJN PJ, JOLES JA: Sympathetic hyperactivity in chronic renal failure: A wake-up call. J Am Soc Nephrol 15:524-537, 2004
40. ELENKOV IJ, WILDER RL, CHROUSOS GP, VIZI ES: The sympathetic nerve-An integrative interface between two supersystems. The brain and immune system. Pharmacol Rev 52:595-638, 2000
41. STENVINKEL P, WANNER C, METZGER T, et al: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 62:1791-1798, 2002
42. PERTICONE F, MAIO R, TRIPEPI G, et al: Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 110:821-825, 2004
43. SHLIPAK MG, FRIED LF, CRUMP C, et al: Cardiovascular disease risk status in elderly persons with renal insufficiency. Kidney Int 62:997-1003, 2002
44. KALOUSOVA M, ZIMA T, TESAR V, et al: Relationship between advanced glycol-oxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney Int (Suppl 84):S62-S64, 2003
45. ZOCCALI C, MALLAMACI F, TRIPEPI G, et al: Fibrinogen mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 254:132-139, 2003
46. KALANTAR ZK, BLOCK G, HUMPHREYS MH, et al: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15:442-453, 2004
47. KRONENBERG F, KUEN E, RITZ E, et al: Lipoprotein (a) serum concentrations and apolipoproteins (a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105-115, 2000
48. ITO A, TSAO PS, ADIMOOLAM S, et al: Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092-3095, 1999
49. CHEN J, MUNTNER P, HAMM LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-174, 2004
50. SCHELLING JR, SEDOR JR: The metabolic syndrome as a risk factor for chronic kidney disease: More than a fat chance? J Am Soc Nephrol 15:2773-2774, 2004
51. BAGBY SP: Obesity-initiated metabolic syndrome and the kidney: A recipe for chronic kidney disease? J Am Soc Nephrol 15:2775-2791, 2004